Clicky

Kangstem Biotech Co. Ltd(217730)

Description: Kangstem Biotech Co., Ltd., a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.


Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Stem Cell Cell Therapy Rheumatoid Arthritis Cell Biology Stem Cell Therapy Mesenchymal Stem Cell Cell Culture Growth Factors Protein Domains Stem Cell Therapy Products

Home Page: www.kangstem.com

Sinan Building
Seoul,
South Korea
Phone: 82 2 888 1590


Officers

Name Title
Mr. Tae-Wha Lee Sr. VP and Internal Director
Dr. Kwang-Won Seo VP and Internal Director

Exchange: KQ

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 8.1981
IPO Date:
Fiscal Year End: December
Full Time Employees: 91
Back to stocks